Document Detail

Repeat intracoronary beta-brachytherapy using a rhenium-188-filled balloon catheter for recurrent restenosis in patients who failed intracoronary radiation therapy.
MedLine Citation:
PMID:  16513516     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Conventional percutaneous coronary intervention (PCI) in restenotic lesions after brachytherapy failure is associated with a high recurrence rate of restenoses and revascularizations. Intracoronary brachytherapy using a liquid rhenium-188-filled balloon in de novo or restenotic lesions safely and effectively reduced restenosis rates. We report clinical and angiographic data regarding the safety and efficacy of rhenium-188 brachytherapy in restenoses after brachytherapy failure. METHODS: Fourteen patients with restenosis after brachytherapy failure received rhenium-188 beta-brachytherapy. Follow-up was performed angiographically after 6 months and clinically after 12 months. Primary clinical endpoint was the incidence of major adverse cardiac events (MACE) defined as any death, myocardial infarction or repeat revascularization in the target vessel within 12 months. Secondary angiographic endpoints were the binary restenosis rate and late loss in the total segment including edge effects at 6 months. RESULTS: The prescribed dose of 22.5 Gy (n=12) or 30 Gy (n=2) was successfully delivered in all patients. In two lesions, a bare-metal stent was implanted. The mean length of the irradiated segment was 40.0+/-15.7 mm. The mean diameter of the irradiation balloon was 2.96+/-0.37 mm. Angiographic follow-up was done in 13 of 14 patients. There was no edge stenosis or coronary aneurysm. Within the total segment, late loss was 0.39+/-0.64 mm and late loss index was 0.18+/-0.40 with a binary restenosis rate of 23%. Twelve months' clinical follow-up was available in all patients, which showed a MACE rate of 7% due to one target lesion revascularization (TLR). CONCLUSIONS: Intracoronary beta-brachytherapy with a liquid rhenium-188-filled balloon in restenoses after intracoronary radiation therapy failure including 12 months combined antiplatelet therapy is safe with respect to vessel thrombosis, late coronary occlusion or aneurysm formation. With limited use of stenting, angiographic and clinical follow-up for repeat brachytherapy were favorable and it is associated with low restenosis and target vessel revascularization rate.
Jochen Wöhrle; Bernd Joachim Krause; Thorsten Nusser; Matthias Kochs; Martin Höher
Related Documents :
19121436 - Paclitaxel-eluting stent long-term outcomes in percutaneous saphenous vein graft interv...
9126666 - The expression of angiotensin-i converting enzyme in human atherosclerotic plaques is n...
10411846 - Primary stenting versus balloon angioplasty in occluded coronary arteries: the total oc...
8316266 - A comparison of directional atherectomy with coronary angioplasty in patients with coro...
8146236 - The croonian lecture, 1993. the endothelium: maestro of the blood circulation.
14671246 - Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cer...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cardiovascular revascularization medicine : including molecular interventions     Volume:  7     ISSN:  1553-8389     ISO Abbreviation:  -     Publication Date:    2006 Jan-Mar
Date Detail:
Created Date:  2006-03-03     Completed Date:  2006-09-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101238551     Medline TA:  Cardiovasc Revasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2-6     Citation Subset:  IM    
Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / instrumentation*
Brachytherapy / instrumentation,  methods*
Chi-Square Distribution
Coronary Angiography
Coronary Restenosis / radiography,  radiotherapy*
Middle Aged
Radioisotopes / therapeutic use*
Radiotherapy Dosage
Rhenium / therapeutic use*
Survival Analysis
Time Factors
Treatment Failure
Treatment Outcome
Reg. No./Substance:
0/Radioisotopes; 7440-15-5/Rhenium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Central corneal thickness and normal tension glaucoma: a cross-sectional study.
Next Document:  Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct...